Amyn Alidina, MD
Medical Oncology · Albuquerque, NMNPI 1821088063
Payments from drug & device makers
Across 75 payments — averaging $77.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$4K
- Johnson & Johnson$257
- E.r. Squibb & Sons, L.L.C.$185
- Boston Scientific$129
- Blue Earth Diagnostics$123
- Progenics Pharmaceuticals, Inc.$104
- plus $721 from 25 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 27 | $4,261 |
| Johnson & Johnson | 4 | $257 |
| E.r. Squibb & Sons, L.L.C. | 5 | $185 |
| Boston Scientific | 1 | $129 |
| Blue Earth Diagnostics | 1 | $123 |
| Progenics Pharmaceuticals, Inc. | 1 | $104 |
| Gilead(2 entities) | 4 | $84 |
| Regeneron Healthcare Solutions, Inc. | 2 | $73 |
| Karyopharm Therapeutics Inc. | 4 | $50 |
| Seagen Inc. | 2 | $50 |
| Bristol Myers Squibb | 2 | $43 |
| AstraZeneca | 2 | $42 |
| Pfizer | 2 | $35 |
| Sanofi | 1 | $31 |
| Genmab U.S., Inc. | 1 | $27 |
| Boehringer Ingelheim | 1 | $26 |
| Eisai Inc. | 1 | $25 |
| Legend Biotech USA Inc. | 1 | $21 |
| Mirati Therapeutics, Inc. | 1 | $21 |
| Blueprint Medicines Corporation | 1 | $20 |
| Puma Biotechnology, Inc. | 1 | $20 |
| Adaptive Biotechnologies Corporation | 1 | $18 |
| Daiichi Sankyo Inc. | 1 | $18 |
| AbbVie | 1 | $17 |
| Astellas Pharma US Inc | 1 | $17 |
| Incyte Corporation | 1 | $16 |
| Ipsen Biopharmaceuticals, Inc | 1 | $15 |
| Beigene USA, Inc. | 1 | $15 |
| Axonics, Inc. | 1 | $14 |
| EMD Serono, Inc. | 1 | $13 |
| Acrotech Biopharma Inc. | 1 | $12 |
How this compares
Too few medical oncology providers in New Mexicoto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other medical oncology in Albuquerque
- Katherine SanchezAlbuquerque$654K
- Atul KumarAlbuquerque$327K
- Annette FontaineAlbuquerque$298K
- Ronald KubicaAlbuquerque$191K
- Richard GiudiceAlbuquerque$18K
- Sofia Palacio CardenasAlbuquerque$9K
- Malcolm PurdyAlbuquerque$7K
- Joseph EkofoAlbuquerque$195
- Colbert ParkerAlbuquerque$103
- Wadih ArapAlbuquerque$0
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.